The experimental treatment, known as Rina-S, met its primary endpoint of progression-free survival while simultaneously hitting a critical secondary goal by improving overall survival rates. These results provide a strong clinical foundation for the drug's potential path toward market approval.
In section Market Quotes
Genmab Ovarian Cancer Drug Succeeds in Phase 3 Trial
Rinatabart sesutecan has cleared key hurdles in a late-stage clinical trial, demonstrating a significant reduction in disease progression among patients with platinum-resistant ovarian cancer. The data from the Phase 3 study marks a pivotal moment for Genmab’s oncology pipeline, sparking a notable rally in the company’s share price.
Following the announcement, Genmab shares climbed 6.8% to reach $42.73 by midday Friday, extending the stock's annual gains to 39%. CEO Jan van de Winkel characterized the findings as a major step toward establishing the firm as a leader in gynecologic oncology. The company is now preparing to initiate discussions with global regulatory authorities to determine the necessary requirements for filing and commercialization.
Comments (0)
No comments yet. Be the first!